Xenetic Biosciences, Inc.

Xenetic Biosciences is a clinical-stage biopharmaceutical company focused on developing immuno-oncology technologies. Its core business model involves advancing biologic drug candidates through preclinical and clinical development, a process that inherently requires animal testing for regulatory compliance and safety assessment. The company’s public filings, including its 2023 10-K report filed with the SEC, explicitly cite the “completion of preclinical laboratory tests, animal studies and formulation studies” as part of its standard development pathway.

The company’s pipeline includes collaborations, such as a 2022 research and development partnership with VolitionRx Limited to develop neutrophil extracellular trap-targeted adoptive cell therapies for oncology. Such preclinical research in immuno-oncology typically involves animal models to evaluate efficacy and toxicology. Third-party screening from Cruelty Free Investors confirms the company’s involvement in animal testing for the research and development of its biologic drugs. As a biopharmaceutical company with no marketed products, its entire valuation is tied to the progression of drug candidates through stages that currently depend on animal data to meet regulatory requirements for human trials.